Viral hybrid vectors for somatic integration - Are they the better solution?

Viruses

Volumn 1, Issue 3, 2009, Pages 1295-1324

  Müther, Nadine ^a   Noske, Nadja ^a   Ehrhardt, Anja ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adeno associated virus; Adenovirus; Herpes simplex virus; PhiC31 integrase; Retrovirus; Sleeping Beauty transposase; Somatic integration; Targeted integration; Vector; Zinc finger nuclease

Indexed keywords

EID: 79961029553     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v1031295     Document Type: Review

References (146)

1. Ivics, Z.; Hackett, P.B.; Plasterk, R.H.; Izsvak, Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997, 91, 501-510.
2. Groth, A.C.; Olivares, E.C.; Thyagarajan, B.; Calos, M.P. A phage integrase directs efficient sitespecific integration in human cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 5995-6000.
3. Groth, A.C.; Calos, M.P. Phage integrases: biology and applications. J. Mol. Biol. 2004, 335, 667-678.
4. Beerli, R.R.; Barbas, C.F., III. Engineering polydactyl zinc-finger transcription factors. Nat. Biotechnol. 2002, 20, 135-141.
5. Carroll, D. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther. 2008, 15, 1463-1468.
6. Knipe, D.M. and Howley P.M. Fields Virology, 5th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2006.
7. Jager, L.; Ehrhardt, A. Persistence of high-capacity adenoviral vectors as replication-defective monomeric genomes in vitro and in murine liver. Hum. Gene Ther. 2009, 20, 883-896.
8. Stephen, S.L.; Sivanandam, V.G.; Kochanek, S. Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J. Gene Med. 2008, 10, 1176-1189.
9. Stabel, S.; Doerfler, W.; Friis, R.R. Integration sites of adenovirus type 12 DNA in transformed hamster cells and hamster tumor cells. J. Virol. 1980, 36, 22-40.
10. Sutter, D.; Westphal, M.; Doerfler, W. Patterns of integration of viral DNA sequences in the genomes of adenovirus type 12-transformed hamster cells. Cell 1978, 14, 569-585.
11. Vogel, S.; Rosahl, T.; Doerfler, W. Chromosomal localization of integrated adenovirus DNA in productively infected and in transformed mammalian cells. Virology 1986, 152, 159-170.
12. Edelstein, M.L.; Abedi, M.R.; Wixon, J. Gene therapy clinical trials worldwide to 2007--an update. J. Gene Med. 2007, 9, 833-842.
13. Benihoud, K.; Yeh, P.; Perricaudet, M. Adenovirus vectors for gene delivery. Curr. Opin. Biotechnol. 1999, 10, 440-447.
14. Andrews, J.L.; Kadan, M.J.; Gorziglia, M.I.; Kaleko, M.; Connelly, S. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol. Ther. 2001, 3, 329-336.
15. Lusky, M.; Christ, M.; Rittner, K.; Dieterle, A.; Dreyer, D.; Mourot, B.; Schultz, H.; Stoeckel, F.; Pavirani, A.; Mehtali, M. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 1998, 72, 2022-2032.
16. Yang, Y.; Ertl, H.C.; Wilson, J.M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994, 1, 433-442.
17. Ehrhardt, A.; Kay, M.A. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002, 99, 3923-3930.
18. Parks, R.J.; Chen, L.; Anton, M.; Sankar, U.; Rudnicki, M.A.; Graham, F.L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U. S. A 1996, 93, 13565-13570.
19. McCaffrey, A.P.; Fawcett, P.; Nakai, H.; McCaffrey, R.L.; Ehrhardt, A.; Pham, T.T.; Pandey, K.; Xu, H.; Feuss, S.; Storm, T.A.; Kay, M.A. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol. Ther. 2008, 16, 931-941.
20. Schiedner, G.; Hertel, S.; Johnston, M.; Biermann, V.; Dries, V.; Kochanek, S. Variables affecting in vivo performance of high-capacity adenovirus vectors. J. Virol. 2002, 76, 1600-1609.
21. Brunetti-Pierri, N.; Grove, N.C.; Zuo, Y.; Edwards, R.; Palmer, D.; Cerullo, V.; Teruya, J.; Ng, P. Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic Index of Gene Therapy Vectors for Hemophilia B. Hum. Gene Ther. 2009, 20, 479-85.
22. Barr, D.; Tubb, J.; Ferguson, D.; Scaria, A.; Lieber, A.; Wilson, C.; Perkins, J.; Kay, M.A. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 1995, 2, 151-155.
23. Ehrhardt, A.; Xu, H.; Kay, M.A. Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J. Virol. 2003, 77, 7689-7695.
24. Soifer, H.S.; Kasahara, N. Retrotransposon-adenovirus hybrid vectors: efficient delivery and stable integration of transgenes via a two-stage mechanism. Curr. Gene Ther. 2004, 4, 373-384.
25. Yant, S.R.; Ehrhardt, A.; Mikkelsen, J.G.; Meuse, L.; Pham, T.; Kay, M.A. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat. Biotechnol. 2002, 20, 999-1005.
26. Ehrhardt, A.; Yant, S.R.; Giering, J.C.; Xu, H.; Engler, J.A.; Kay, M.A. Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo. Mol. Ther. 2007, 15, 146-156.
27. Murphy, S.J.; Chong, H.; Bell, S.; Diaz, R.M.; Vile, R.G. Novel integrating adenoviral/retroviral hybrid vector for gene therapy. Hum. Gene Ther. 2002, 13, 745-760.
28. Zheng, C.; Baum, B.J.; Iadarola, M.J.; O'Connell, B.C. Genomic integration and gene expression by a modified adenoviral vector. Nat. Biotechnol. 2000, 18, 176-180.
29. Goncalves, M.A.; Holkers, M.; Cudre-Mauroux, C.; van Nierop, G.P.; Knaan-Shanzer, S.; van, d. V., I; Valerio, D.; de Vries, A.A. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells. Mol. Ther. 2006, 13, 976-986.
30. Goncalves, M.A.; Holkers, M.; van Nierop, G.P.; Wieringa, R.; Pau, M.G.; de Vries, A.A. Targeted chromosomal insertion of large DNA into the human genome by a fiber-modified highcapacity adenovirus-based vector system. PLoS One 2008, 3, e3084.
31. Recchia, A.; Parks, R.J.; Lamartina, S.; Toniatti, C.; Pieroni, L.; Palombo, F.; Ciliberto, G.; Graham, F.L.; Cortese, R.; La, M.N.; Colloca, S. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc. Natl. Acad. Sci. U. S. A 1999, 96, 2615-2620.
32. Fisher, K.J.; Kelley, W.M.; Burda, J.F.; Wilson, J.M. A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum. Gene Ther. 1996, 7, 2079-2087.
33. Kotin, R.M.; Siniscalco, M.; Samulski, R.J.; Zhu, X.D.; Hunter, L.; Laughlin, C.A.; McLaughlin, S.; Muzyczka, N.; Rocchi, M.; Berns, K.I. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 2211-2215.
34. Linden, R.M.; Ward, P.; Giraud, C.; Winocour, E.; Berns, K.I. Site-specific integration by adenoassociated virus. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 11288-11294.
35. Samulski, R.J.; Zhu, X.; Xiao, X.; Brook, J.D.; Housman, D.E.; Epstein, N.; Hunter, L.A. Targeted integration of adeno-associated virus(AAV) into human chromosome 19. EMBO J. 1991, 10, 3941-3950.
36. Nakai, H.; Montini, E.; Fuess, S.; Storm, T.A.; Grompe, M.; Kay, M.A. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. 2003, 34, 297-302.
37. Nakai, H.; Thomas, C.E.; Storm, T.A.; Fuess, S.; Powell, S.; Wright, J.F.; Kay, M.A. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J. Virol. 2002, 76, 11343-11349.
38. Lieber, A.; Steinwaerder, D.S.; Carlson, C.A.; Kay, M.A. Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J. Virol. 1999, 73, 9314-9324.
39. Sandalon, Z.; Gnatenko, D.V.; Bahou, W.F.; Hearing, P. Adeno-associated virus(AAV) Rep protein enhances the generation of a recombinant mini-adenovirus(Ad) utilizing an Ad/AAV hybrid virus. J. Virol. 2000, 74, 10381-10389.
40. Shayakhmetov, D.M.; Carlson, C.A.; Stecher, H.; Li, Q.; Stamatoyannopoulos, G.; Lieber, A. A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. J. Virol. 2002, 76, 1135-1143.
41. Goncalves, M.A.; Pau, M.G.; de Vries, A.A.; Valerio, D. Generation of a high-capacity hybrid vector: packaging of recombinant adenoassociated virus replicative intermediates in adenovirus capsids overcomes the limited cloning capacity of adenoassociated virus vectors. Virology 2001, 288, 236-246.
42. Goncalves, M.A.; van, V., I; Janssen, J.M.; Maassen, B.T.; Heemskerk, E.H.; Opstelten, D.J.; Knaan-Shanzer, S.; Valerio, D.; de Vries, A.A. Efficient generation and amplification of highcapacity adeno-associated virus/adenovirus hybrid vectors. J. Virol. 2002, 76, 10734-10744.
43. Recchia, A.; Perani, L.; Sartori, D.; Olgiati, C.; Mavilio, F. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther. 2004, 10, 660-670.
44. Ivics, Z.; Izsvak, Z. Transposons for gene therapy! Curr. Gene Ther. 2006, 6, 593-607.
45. Yant, S.R.; Wu, X.; Huang, Y.; Garrison, B.; Burgess, S.M.; Kay, M.A. High-resolution genomewide mapping of transposon integration in mammals. Mol. Cell Biol. 2005, 25, 2085-2094.
46. Mikkelsen, J.G.; Yant, S.R.; Meuse, L.; Huang, Z.; Xu, H.; Kay, M.A. Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Mol. Ther. 2003, 8, 654-665.
47. Yant, S.R.; Meuse, L.; Chiu, W.; Ivics, Z.; Izsvak, Z.; Kay, M.A. Somatic integration and longterm transgene expression in normal and haemophilic mice using a DNA transposon system. Nat. Genet. 2000, 25, 35-41.
48. Mates, L.; Chuah, M.K.; Belay, E.; Jerchow, B.; Manoj, N.; costa-Sanchez, A.; Grzela, D.P.; Schmitt, A.; Becker, K.; Matrai, J.; Ma, L.; Samara-Kuko, E.; Gysemans, C.; Pryputniewicz, D.; Miskey, C.; Fletcher, B.; Vandendriessche, T.; Ivics, Z.; Izsvak, Z. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet. 2009, 41, 753-761.
49. Kuhstoss, S.; Rao, R.N. Analysis of the integration function of the streptomycete bacteriophage phi C31. J. Mol. Biol. 1991, 222, 897-908.
50. Chalberg, T.W.; Portlock, J.L.; Olivares, E.C.; Thyagarajan, B.; Kirby, P.J.; Hillman, R.T.; Hoelters, J.; Calos, M.P. Integration specificity of phage PhiC31 integrase in the human genome. J Mol. Biol. 2006, 357, 28-48.
51. Ehrhardt, A.; Engler, J.A.; Xu, H.; Cherry, A.M.; Kay, M.A. Molecular analysis of chromosomal rearrangements in mammalian cells after PhiC31-mediated integration. Hum. Gene Ther. 2006, 17, 1077-1094.
52. Olivares, E.C.; Hollis, R.P.; Chalberg, T.W.; Meuse, L.; Kay, M.A.; Calos, M.P. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat. Biotechnol. 2002, 20, 1124-1128.
53. Thyagarajan, B.; Olivares, E.C.; Hollis, R.P.; Ginsburg, D.S.; Calos, M.P. Site-specific genomic integration in mammalian cells mediated by phage PhiC31 integrase. Mol. Cell Biol. 2001, 21, 3926-3934.
54. Soifer, H.; Higo, C.; Kazazian, H.H., Jr.; Moran, J.V.; Mitani, K.; Kasahara, N. Stable integration of transgenes delivered by a retrotransposon-adenovirus hybrid vector. Hum. Gene Ther. 2001, 12, 1417-1428.
55. Kubo, S.; Seleme, M.C.; Soifer, H.S.; Perez, J.L.; Moran, J.V.; Kazazian, H.H., Jr.; Kasahara, N. L1 retrotransposition in nondividing and primary human somatic cells. Proc. Natl. Acad. Sci. U. S. A 2006, 103, 8036-8041.
56. Caplen, N.J.; Higginbotham, J.N.; Scheel, J.R.; Vahanian, N.; Yoshida, Y.; Hamada, H.; Blaese, R.M.; Ramsey, W.J. Adeno-retroviral chimeric viruses as in vivo transducing agents. Gene Ther. 1999, 6, 454-459.
57. Duisit, G.; Salvetti, A.; Moullier, P.; Cosset, F.L. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines. Hum. Gene Ther. 1999, 10, 189-200.
58. Feng, M.; Jackson, W.H., Jr.; Goldman, C.K.; Rancourt, C.; Wang, M.; Dusing, S.K.; Siegal, G.; Curiel, D.T. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat. Biotechnol. 1997, 15, 866-870.
59. Picard-Maureau, M.; Kreppel, F.; Lindemann, D.; Juretzek, T.; Herchenroder, O.; Rethwilm, A.; Kochanek, S.; Heinkelein, M. Foamy virus--adenovirus hybrid vectors. Gene Ther. 2004, 11, 722-728.
60. Nawa, A.; Luo, C.; Zhang, L.; Ushjima, Y.; Ishida, D.; Kamakura, M.; Fujimoto, Y.; Goshima, F.; Kikkawa, F.; Nishiyama, Y. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr. Gene Ther. 2008, 8, 208-221.
61. Spaete, R.R.; Frenkel, N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982, 30, 295-304.
62. Sena-Esteves, M.; Saeki, Y.; Fraefel, C.; Breakefield, X.O. HSV-1 amplicon vectors--simplicity and versatility. Mol. Ther. 2000, 2, 9-15.
63. Wade-Martins, R.; Smith, E.R.; Tyminski, E.; Chiocca, E.A.; Saeki, Y. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat. Biotechnol. 2001, 19, 1067-1070.
64. Epstein, A.L. HSV-1-derived amplicon vectors: recent technological improvements and remaining difficulties--a review. Mem. Inst. Oswaldo Cruz 2009, 104, 399-410.
65. Heister, T.; Heid, I.; Ackermann, M.; Fraefel, C. Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. J. Virol. 2002, 76, 7163-7173.
66. Wang, Y.; Camp, S.M.; Niwano, M.; Shen, X.; Bakowska, J.C.; Breakefield, X.O.; Allen, P.D. Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. J. Virol. 2002, 76, 7150-7162.
67. Johnston, K.M.; Jacoby, D.; Pechan, P.A.; Fraefel, C.; Borghesani, P.; Schuback, D.; Dunn, R.J.; Smith, F.I.; Breakefield, X.O. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum. Gene Ther. 1997, 8, 359-370.
68. Cortes, M.L.; Oehmig, A.; Saydam, O.; Sanford, J.D.; Perry, K.F.; Fraefel, C.; Breakefield, X.O. Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. Mol. Ther. 2008, 16, 81-88.
69. Liu, J.; Jeppesen, I.; Nielsen, K.; Jensen, T.G. Phi c31 integrase induces chromosomal aberrations in primary human fibroblasts. Gene Ther. 2006, 13, 1188-1190.
70. Oehmig, A.; Cortes, M.L.; Perry, K.F.; Sena-Esteves, M.; Fraefel, C.; Breakefield, X.O. Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector. Gene Ther. 2007, 14, 1078-1091.
71. Bowers, W.J.; Mastrangelo, M.A.; Howard, D.F.; Southerland, H.A.; Maguire-Zeiss, K.A.; Federoff, H.J. Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector. Mol. Ther. 2006, 13, 580-588.
72. Savard, N.; Cosset, F.L.; Epstein, A.L. Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors. J. Virol. 1997, 71, 4111-4117.
73. Sena-Esteves, M.; Saeki, Y.; Camp, S.M.; Chiocca, E.A.; Breakefield, X.O. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J. Virol. 1999, 73, 10426-10439.
74. de Felipe, P.; Izquierdo, M.; Wandosell, F.; Lim, F. Integrating retroviral cassette extends gene delivery of HSV-1 expression vectors to dividing cells. Biotechniques 2001, 31, 394-395.
75. Blaese, R.M.; Culver, K.W.; Miller, A.D.; Carter, C.S.; Fleisher, T.; Clerici, M.; Shearer, G.; Chang, L.; Chiang, Y.; Tolstoshev, P.; Greenblatt, J.J.; Rosenberg, S.A.; Klein, H.; Berger, M.; Mullen, C.A.; Ramsey, W.J.; Muul, L.; Morgan, R.A.; Anderson, W.F. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995, 270, 475-480.
76. Arrigo, S.J.; Weitsman, S.; Zack, J.A.; Chen, I.S. Characterization and expression of novel singly spliced RNA species of human immunodeficiency virus type 1. J. Virol. 1990, 64, 4585-4588.
77. Coffin, J.M. Structure, replication, and recombination of retrovirus genomes: some unifying hypotheses. J. Gen. Virol. 1979, 42, 1-26.
78. Coffin, J.M. Retroviral DNA integration. Dev. Biol. Stand. 1992, 76, 141-151.
79. Daniel, R.; Katz, R.A.; Skalka, A.M. A role for DNA-PK in retroviral DNA integration. Science 1999, 284, 644-647.
80. Skalka, A.M.; Katz, R.A. Retroviral DNA integration and the DNA damage response. Cell Death Differ. 2005, 12, 971-978.
81. Smith, J.A.; Daniel, R. Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses. ACS Chem. Biol. 2006, 1, 217-226.
82. Mitchell, R.S.; Beitzel, B.F.; Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS. Biol. 2004, 2, E234.
83. Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110, 521-529.
84. Lewinski, M.K.; Yamashita, M.; Emerman, M.; Ciuffi, A.; Marshall, H.; Crawford, G.; Collins, F.; Shinn, P.; Leipzig, J.; Hannenhalli, S.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS. Pathog. 2006, 2, e60.
85. Wu, X.; Li, Y.; Crise, B.; Burgess, S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300, 1749-1751.
86. Trobridge, G.D.; Miller, D.G.; Jacobs, M.A.; Allen, J.M.; Kiem, H.P.; Kaul, R.; Russell, D.W. Foamy virus vector integration sites in normal human cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 1498-1503.
87. Derse, D.; Crise, B.; Li, Y.; Princler, G.; Lum, N.; Stewart, C.; McGrath, C.F.; Hughes, S.H.; Munroe, D.J.; Wu, X. Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J. Virol. 2007, 81, 6731-6741.
88. Hacein-Bey-Abina, S.; Von, K.C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Leboulch, P.; Lim, A.; Osborne, C.S.; Pawliuk, R.; Morillon, E.; Sorensen, R.; Forster, A.; Fraser, P.; Cohen, J. I.; de Saint, B.G.; Alexander, I.; Wintergerst, U.; Frebourg, T.; Aurias, A.; Stoppa-Lyonnet, D.; Romana, S.; Radford-Weiss, I.; Gross, F.; Valensi, F.; Delabesse, E.; Macintyre, E.; Sigaux, F.; Soulier, J.; Leiva, L.E.; Wissler, M.; Prinz, C.; Rabbitts, T.H.; Le, D.F.; Fischer, A.; Cavazzana-Calvo, M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302, 415-419.
89. Li, Z.; Dullmann, J.; Schiedlmeier, B.; Schmidt, M.; Von, K.C.; Meyer, J.; Forster, M.; Stocking, C.; Wahlers, A.; Frank, O.; Ostertag, W.; Kuhlcke, K.; Eckert, H.G.; Fehse, B.; Baum, C. Murine leukemia induced by retroviral gene marking. Science 2002, 296, 497.
90. Tomanin, R.; Scarpa, M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr. Gene Ther. 2004, 4, 357-372.
91. Bushman, F.D. Tethering human immunodeficiency virus 1 integrase to a DNA site directs integration to nearby sequences. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 9233-9237.
92. Bushman, F.D.; Miller, M.D. Tethering human immunodeficiency virus type 1 preintegration complexes to target DNA promotes integration at nearby sites. J. Virol. 1997, 71, 458-464.
93. Goulaouic, H.; Chow, S.A. Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. J. Virol. 1996, 70, 37-46.
94. Katz, R.A.; Merkel, G.; Skalka, A.M. Targeting of retroviral integrase by fusion to a heterologous DNA binding domain: in vitro activities and incorporation of a fusion protein into viral particles. Virology 1996, 217, 178-190.
95. Tan, W.; Dong, Z.; Wilkinson, T.A.; Barbas, C.F., III; Chow, S.A. Human immunodeficiency virus type 1 incorporated with fusion proteins consisting of integrase and the designed polydactyl zinc finger protein E2C can bias integration of viral DNA into a predetermined chromosomal region in human cells. J. Virol. 2006, 80, 1939-1948.
96. Beerli, R.R.; Segal, D.J.; Dreier, B.; Barbas, C.F., III. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 14628-14633.
97. Beerli, R.R.; Dreier, B.; Barbas, C.F., III. Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 1495-1500.
98. Vargas, J., Jr.; Gusella, G.L.; Najfeld, V.; Klotman, M.E.; Cara, A. Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum. Gene Ther. 2004, 15, 361-372.
99. Moldt, B.; Staunstrup, N.H.; Jakobsen, M.; Yanez-Munoz, R.J.; Mikkelsen, J.G. Genomic insertion of lentiviral DNA circles directed by the yeast Flp recombinase. BMC. Biotechnol. 2008, 8, 60.
100. Nightingale, S.J.; Hollis, R.P.; Pepper, K.A.; Petersen, D.; Yu, X.J.; Yang, C.; Bahner, I.; Kohn, D.B. Transient gene expression by nonintegrating lentiviral vectors. Mol. Ther. 2006, 13, 1121-1132.
101. Lombardo, A.; Genovese, P.; Beausejour, C.M.; Colleoni, S.; Lee, Y.L.; Kim, K.A.; Ando, D.; Urnov, F.D.; Galli, C.; Gregory, P.D.; Holmes, M.C.; Naldini, L. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat. Biotechnol. 2007, 25, 1298-1306.
102. Bitinaite, J.; Wah, D.A.; Aggarwal, A.K.; Schildkraut, I. FokI dimerization is required for DNA cleavage. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 10570-10575.
103. Cornu, T.I.; Thibodeau-Beganny, S.; Guhl, E.; Alwin, S.; Eichtinger, M.; Joung, J.K.; Cathomen, T. DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. Mol. Ther. 2008, 16, 352-358.
104. Cahill, D.; Connor, B.; Carney, J.P. Mechanisms of eukaryotic DNA double strand break repair. Front Biosci. 2006, 11, 1958-1976.
105. Staunstrup, N.H.; Moldt, B.; Mates, L.; Villesen, P.; Jakobsen, M.; Ivics, Z.; Izsvak, Z.; Mikkelsen, J.G. Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol. Ther. 2009, 17, 1205-1214.
106. Vink, C.A.; Gaspar, H.B.; Gabriel, R.; Schmidt, M.; McIvor, R.S.; Thrasher, A.J.; Qasim, W. Sleeping beauty transposition from nonintegrating lentivirus. Mol. Ther. 2009, 17, 1197-1204.
107. Williams, D.A. Sleeping beauty vector system moves toward human trials in the United States. Mol. Ther. 2008, 16, 1515-1516.
108. Liu, J.; Skjorringe, T.; Gjetting, T.; Jensen, T.G. PhiC31 integrase induces a DNA damage response and chromosomal rearrangements in human adult fibroblasts. BMC. Biotechnol. 2009, 9, 31.
109. Alwin, S.; Gere, M.B.; Guhl, E.; Effertz, K.; Barbas, C.F., III; Segal, D.J.; Weitzman, M.D.; Cathomen, T. Custom zinc-finger nucleases for use in human cells. Mol. Ther. 2005, 12, 610-617.
110. Porteus, M.H.; Baltimore, D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003, 300, 763.
111. Miller, J.C.; Holmes, M.C.; Wang, J.; Guschin, D.Y.; Lee, Y.L.; Rupniewski, I.; Beausejour, C.M.; Waite, A.J.; Wang, N.S.; Kim, K.A.; Gregory, P.D.; Pabo, C.O.; Rebar, E.J. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 2007, 25, 778-785.
112. Szczepek, M.; Brondani, V.; Buchel, J.; Serrano, L.; Segal, D.J.; Cathomen, T. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat. Biotechnol. 2007, 25, 786-793.
113. Hamilton, H.; Gomos, J.; Berns, K.I.; Falck-Pedersen, E. Adeno-associated virus site-specific integration and AAVS1 disruption. J. Virol. 2004, 78, 7874-7882.
114. Tan, I.; Ng, C.H.; Lim, L.; Leung, T. Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton. J. Biol. Chem. 2001, 276, 21209-21216.
115. Calcedo, R.; Vandenberghe, L.H.; Gao, G.; Lin, J.; Wilson, J.M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 2009, 199, 381-390.
116. Halbert, C.L.; Miller, A.D.; McNamara, S.; Emerson, J.; Gibson, R.L.; Ramsey, B.; Aitken, M.L. Prevalence of neutralizing antibodies against adeno-associated virus(AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 2006, 17, 440-447.
117. Antoni, B.A.; Rabson, A.B.; Miller, I.L.; Trempe, J.P.; Chejanovsky, N.; Carter, B.J. Adenoassociated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells. J. Virol. 1991, 65, 396-404.
118. Schmidt, M.; Afione, S.; Kotin, R.M. Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p53. J. Virol. 2000, 74, 9441-9450.
119. Yang, Q.; Chen, F.; Trempe, J.P. Characterization of cell lines that inducibly express the adenoassociated virus Rep proteins. J. Virol. 1994, 68, 4847-4856.
120. Modlich, U.; Bohne, J.; Schmidt, M.; Von, K.C.; Knoss, S.; Schambach, A.; Baum, C. Cellculture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006, 108, 2545-2553.
121. Montini, E.; Cesana, D.; Schmidt, M.; Sanvito, F.; Ponzoni, M.; Bartholomae, C.; Sergi, S.L.; Benedicenti, F.; Ambrosi, A.; Di, S.C.; Doglioni, C.; Von, K.C.; Naldini, L. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 2006, 24, 687-696.
122. Allocca, M.; Doria, M.; Petrillo, M.; Colella, P.; Garcia-Hoyos, M.; Gibbs, D.; Kim, S.R.; Maguire, A.; Rex, T.S.; Di, V.U.; Cutillo, L.; Sparrow, J.R.; Williams, D.S.; Bennett, J.; Auricchio, A. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J. Clin. Invest. 2008, 118, 1955-1964.
123. Hockemeyer, D.; Soldner, F.; Beard, C.; Gao, Q.; Mitalipova, M.; DeKelver, R.C.; Katibah, G.E.; Amora, R.; Boydston, E.A.; Zeitler, B.; Meng, X.; Miller, J.C.; Zhang, L.; Rebar, E.J.; Gregory, P.D.; Urnov, F.D.; Jaenisch, R. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. Biotechnol. 2009, 27, 851-857.
124. Ivics, Z.; Katzer, A.; Stuwe, E.E.; Fiedler, D.; Knespel, S.; Izsvak, Z. Targeted Sleeping Beauty transposition in human cells. Mol. Ther. 2007, 15, 1137-1144.
125. Yant, S.R.; Huang, Y.; Akache, B.; Kay, M.A. Site-directed transposon integration in human cells. Nucleic Acids Res. 2007, 35, e50.
126. Keravala, A.; Lee, S.; Thyagarajan, B.; Olivares, E.C.; Gabrovsky, V.E.; Woodard, L.E.; Calos, M.P. Mutational derivatives of PhiC31 integrase with increased efficiency and specificity. Mol. Ther. 2009, 17, 112-120.
127. Brown, B.D.; Naldini, L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 2009, 10, 578-585.
128. Buchholz, C.J.; Muhlebach, M.D.; Cichutek, K. Lentiviral vectors with measles virus glycoproteins-dream team for gene transfer? Trends Biotechnol. 2009, 27, 259-265.
129. Frampton, A.R., Jr.; Goins, W.F.; Nakano, K.; Burton, E.A.; Glorioso, J.C. HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther. 2005, 12, 891-901.
130. Kwon, I.; Schaffer, D.V. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm. Res. 2008, 25, 489-499.
131. Van, V.K.; Mohiuddin, Y.; McClung, S.; Blouin, V.; Rolling, F.; Moullier, P.; gbandje-McKenna, M.; Snyder, R.O. Adeno-associated virus capsid serotype identification: Analytical methods development and application. J. Virol. Methods 2009, 159, 167-177.
132. Yu, J.H.; Schaffer, D.V. Advanced targeting strategies for murine retroviral and adeno-associated viral vectors. Adv. Biochem. Eng. Biotechnol. 2005, 99, 147-167.
133. Costantini, L.C.; Jacoby, D.R.; Wang, S.; Fraefel, C.; Breakefield, X.O.; Isacson, O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther. 1999, 10, 2441-2443.
134. Ueno, T.; Matsumura, H.; Tanaka, K.; Iwasaki, T.; Ueno, M.; Fujinaga, K.; Asada, K.; Kato, I. Site-specific integration of a transgene mediated by a hybrid adenovirus/adeno-associated virus vector using the Cre/loxP-expression-switching system. Biochem. Biophys. Res. Commun. 2000, 273, 473-478.
135. Broberg, E.K.; Hukkanen, V. Immune response to herpes simplex virus and gamma134.5 deleted HSV vectors. Curr. Gene Ther. 2005, 5, 523-530.
136. Follenzi, A.; Santambrogio, L.; Annoni, A. Immune responses to lentiviral vectors. Curr. Gene Ther. 2007, 7, 306-315.
137. Seiler, M.P.; Cerullo, V.; Lee, B. Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects. Curr. Gene Ther. 2007, 7, 297-305.
138. Yant, S.R.; Park, J.; Huang, Y.; Mikkelsen, J.G.; Kay, M.A. Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol. Cell Biol. 2004, 24, 9239-9247.
139. Baum, C.; Von, K.C.; Staal, F.J.; Li, Z.; Fehse, B.; Schmidt, M.; Weerkamp, F.; Karlsson, S.; Wagemaker, G.; Williams, D.A. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol. Ther. 2004, 9, 5-13.
140. Walisko, O.; Schorn, A.; Rolfs, F.; Devaraj, A.; Miskey, C.; Izsvak, Z.; Ivics, Z. Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. Mol. Ther. 2008, 16, 359-369.
141. Kuate, S.; Stefanou, D.; Hoffmann, D.; Wildner, O.; Uberla, K. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses. J. Gene Med. 2004, 6, 1197-1205.
142. Kubo, S.; Mitani, K. A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. J. Virol. 2003, 77, 2964-2971.
143. Soifer, H.; Higo, C.; Logg, C.R.; Jih, L.J.; Shichinohe, T.; Harboe-Schmidt, E.; Mitani, K.; Kasahara, N. A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism. Mol. Ther. 2002, 5, 599-608.
144. Geurts, A.M.; Yang, Y.; Clark, K.J.; Liu, G.; Cui, Z.; Dupuy, A.J.; Bell, J.B.; Largaespada, D.A.; Hackett, P.B. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol. Ther. 2003, 8, 108-117.
145. Robert, M.A.; Benoit, R.; Desfosse, L.; Mairey, E.; Tremblay, J.P.; Massie, B.; Gilbert, R. Integration site mapping of linear and circular gutless adenovirus mediated by the phage phiC31 integrase. In Abstract book of American Society of Gene Therapy, R.M. Frederickson: Seattle, WA, USA, 2009; p. S46.
146. Niemeyer, G.P.; Herzog, R.W.; Mount, J.; Arruda, V.R.; Tillson, D.M.; Hathcock, J.; van Ginkel, F.W.; High, K.A.; Lothrop, C.D. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009, 113, 797-806.